IRVINE, Calif., April 14, 2025--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the ...
A Japanese center found that hemolysis was significantly more common after TAVR with the Sapien 3 Ultra Resilia than with its predecessor device, despite the improvement on paravalvular leaks. Annular ...
Edwards Lifesciences EW has announced one-year, real-world data on its SAPIEN 3 Ultra RESILIA valve at the PCR London Valves 2024. These data add to the extensive body of evidence on the company’s ...
A new propensity-matched analysis looking at 5-year clinical outcomes in intermediate-risk patients with severe symptomatic aortic stenosis shows similar rates of all-cause mortality and stroke among ...
As legal battles continue between the manufacturers, the COMPARE-TAVI 1 trial has demonstrated that the Myval and Myval Octacor transcatheter heart valves (Meril Life Sciences) compare favorably with ...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach ...
Edwards Lifesciences Corporation EW recently launched the SAPIEN 3 Ultra RESILIA valve post the FDA approval of the same. The SAPIEN 3 Ultra RESILIA valve comprises the breakthrough RESILIA tissue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results